- Home
- AUUD vs ADTX Comparison
AUUD vs ADTX Comparison
Compare AUUD & ADTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AUUD
- ADTX
- Stock Information
- Founded
- AUUD 2012
- ADTX 2017
- Country
- AUUD United States
- ADTX United States
- Employees
- AUUD N/A
- ADTX N/A
- Industry
- AUUD Computer Software: Prepackaged Software
- ADTX Biotechnology: Pharmaceutical Preparations
- Sector
- AUUD Technology
- ADTX Health Care
- Exchange
- AUUD Nasdaq
- ADTX Nasdaq
- Market Cap
- AUUD 2.8M
- ADTX 3.1M
- IPO Year
- AUUD 2021
- ADTX 2020
- Fundamental
- Price
- AUUD $2.65
- ADTX $1.03
- Analyst Decision
- AUUD
- ADTX
- Analyst Count
- AUUD 0
- ADTX 0
- Target Price
- AUUD N/A
- ADTX N/A
- AVG Volume (30 Days)
- AUUD 2.5M
- ADTX 491.9K
- Earning Date
- AUUD 08-19-2025
- ADTX 08-18-2025
- Dividend Yield
- AUUD N/A
- ADTX N/A
- EPS Growth
- AUUD N/A
- ADTX N/A
- EPS
- AUUD N/A
- ADTX N/A
- Revenue
- AUUD N/A
- ADTX $55,323.00
- Revenue This Year
- AUUD N/A
- ADTX $15,768.94
- Revenue Next Year
- AUUD N/A
- ADTX N/A
- P/E Ratio
- AUUD N/A
- ADTX N/A
- Revenue Growth
- AUUD N/A
- ADTX N/A
- 52 Week Low
- AUUD $2.37
- ADTX $0.81
- 52 Week High
- AUUD $31.62
- ADTX $11,700.00
- Technical
- Relative Strength Index (RSI)
- AUUD 34.45
- ADTX 41.24
- Support Level
- AUUD $2.37
- ADTX $0.81
- Resistance Level
- AUUD $3.78
- ADTX $1.29
- Average True Range (ATR)
- AUUD 0.60
- ADTX 0.12
- MACD
- AUUD -0.19
- ADTX 0.01
- Stochastic Oscillator
- AUUD 7.16
- ADTX 44.00
About AUUD Auddia Inc.
Auddia Inc is a technology company that is engaged in radio broadcasts and streaming audio content digitally. Its products includes Auddia App which is a subscription-based commercial-free AM/FM software application, and Vodacast an interactive podcasting platform and application. The company generates revenue through subscription fees from customers accessing the company's cloud-based computing services and advertisement services.
About ADTX Aditxt Inc.
Aditxt Inc is a life sciences company that develops, builds, and grows innovations with a focus on monitoring and modulating the immune system. It develops products designed to induce tolerance to transplanted organs. Its portfolio consists of two programs Adimune and AditxtScore. It firm's immunosuppressive (anti-rejection) drugs have made possible life-saving organ transplantation procedures and blocking of unwanted immune responses in autoimmune diseases. It is also developing a technology called Apoptotic DNA Immunotherapy (ADi) ADI-100, which utilizes a novel approach that mimics, the way bodies naturally induce tolerance to tissues.